AB Science has received a binding offer for a Clinical Trial Funding Insurance policy from Medical & Commercial International Ltd. (MCI), Lloyd's Syndicate 1902, for its Phase III clinical trial ...

AB Science S.A. (the "Company" or "AB Science", Euronext – FR0010557264 – AB) announces today that it reached an agreement with a historical investor on a financing of USD 8.5 million through the ...

AB Science SA (Euronext - FR0010557264 - AB) today announced that new analyses from its phase 3 trial in amyotrophic lateral sclerosis (AB10015) and preclinical animal model data have been accepted ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Appointment of Stéphane Ledermann as Chairman and Chief Executive Officer In-depth overhaul of the Company's organisation and strategy Priority given to the development of a new quality assurance ...

(RTTNews) - French pharmaceutical company AB Science SA (ABSCF.PK) announced Monday that it has received Chinese patent protecting Masitinib in the treatment of Covid-19 until April 2041. In Paris, AB ...

i) Approval by several European countries to initiate the confirmatory Phase 3 trial AB Science announced in July 2025 that the confirmatory Phase 3 trial with masitinib in amyotrophic lateral ...

AB Science SA (Euronext - FR0010557264 - AB) today announced that the United States Patent Office has issued a Notice of Allowance for a patent relating to methods of treating sickle cell disease (i.e ...

ARTICLE FROM THE LEADING PUBLICATION LIFE SCIENCES MAGAZINE FEATURING AB SCIENCE'S MASITINIB AND ITS PHASE 3 PRINCIPAL INVESTIGATOR, THE NEUROLOGIST PATRICK VERMERSCH Paris, March 04, 2025, 8.30am CET ...